Matthew T. Wiley
CIK 1759703 · Chief Commercial Officer · last filed 2026-02-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.95M
Companies
6
Total Filings
28
Lifetime Open-Market Net
$44.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Commercial Officer | 115,000 | $24.75 | $2.85M | $0 | 1 | 2026-02-05 |
| BTAI | Chief Commercial Officer | 25,283 | $1.14 | $28.8K | -$6.6K | 8 | 2025-04-01 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Commercial Officer | — | $15.00 | — | $0 | 1 | 2025-03-18 |
| VYNE | Chief Commercial Officer | 109,246 | $0.65 | $70.8K | $0 | 6 | 2021-07-02 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Commercial Officer | 352,425 | — | — | $0 | 5 | 2020-07-02 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Chief Commercial Officer | 114,074 | — | — | $50.5K | 6 | 2020-03-03 |
Recent Filings · Page 3 of 3
28 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-03-11 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | +67,576 | $0 | EDGAR |
| 2020-03-11 | — | Disp (D) | −114,074 | $0 | |
| 2020-03-03 | Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Grant (A) | +1,993 | $5.3K | EDGAR |
| 2020-02-24 | Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Grant (A) | +41,299 | $0 | EDGAR |
| 2020-01-03 | Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Tax (F) | −2,500 | -$8.2K | EDGAR |
| 2019-12-03 | Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Grant (A) | +9,842 | $21.2K | EDGAR |
| 2019-03-06 | Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Buy (P) | +13,440 | $50.5K | EDGAR |
| 2018-12-04 | Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Grant (A) | +50,000 | $0 | EDGAR |
Showing 21–28 of 28
Prev
Page 3 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.